3 hours Morgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN) MarketBeat
Morgan Stanley reiterated an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday.
Morgan Stanley (MS) · Nasdaq 100